Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Change in Accured Expenses: 2015-2025

Historic Change in Accured Expenses for Intellia Therapeutics (NTLA) over the last 11 years, with Sep 2025 value amounting to -$715,000.

  • Intellia Therapeutics' Change in Accured Expenses fell 111.50% to -$715,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.3 million, marking a year-over-year decrease of 95.04%. This contributed to the annual value of -$10.4 million for FY2024, which is 272.36% down from last year.
  • Intellia Therapeutics' Change in Accured Expenses amounted to -$715,000 in Q3 2025, which was down 185.94% from $832,000 recorded in Q2 2025.
  • Over the past 5 years, Intellia Therapeutics' Change in Accured Expenses peaked at $18.4 million during Q4 2021, and registered a low of -$22.4 million during Q1 2024.
  • Moreover, its 3-year median value for Change in Accured Expenses was $1.8 million (2024), whereas its average is -$1.7 million.
  • The largest annual percentage gain for Intellia Therapeutics' Change in Accured Expenses in the last 5 years was 552.33% (2021), contrasted with its biggest fall of 2,692.09% (2021).
  • Quarterly analysis of 5 years shows Intellia Therapeutics' Change in Accured Expenses stood at $18.4 million in 2021, then plummeted by 83.33% to $3.1 million in 2022, then soared by 194.01% to $9.0 million in 2023, then slumped by 56.23% to $4.0 million in 2024, then tumbled by 111.50% to -$715,000 in 2025.
  • Its Change in Accured Expenses stands at -$715,000 for Q3 2025, versus $832,000 for Q2 2025 and -$14.4 million for Q1 2025.